Loading
Protalix BioTherapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bashan Dror, was filed 23 Dec 2025.
Protalix BioTherapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Protalix BioTherapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Israel. The group dates from 1993. Over the twelve months to 22 October 2026, 2 filings were filed, from 2 insiders.
Open-market activity splits into 1 purchase totalling €86k and 1 sale totalling €271; 1 insider sit on the buying side and 1 insider on the selling side. Purchases outweigh sales by €86k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €86k, bought by Bashan Dror and made public on 23 December 2025. Those buying include 1 chief executive.
For context, the typical company on the same exchange (median of 2,023 companies) published 41 filings over the same period, against 2 filings here. Over the whole record (from 2016), the tally stands at 8 purchases and 4 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 52.7 m USD and net income at -6.6 m USD.
The clock since the last published purchase (23 December 2025) now reads 305 days.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
35
Thresholds
n/a
Buy Volume
€770,864
8 ops. · all time
Sell Volume
€2M
4 ops. · all time
Who traded when
BuySaleAharon Schwartz1 buy
Amos Bar-Shalev1 sale
Dror Bashan1 buy
Since the insiders bought
- +16.9%Entry US$1.77 · Close at T+90 US$2.07
- +46.6%Entry US$1.61 · Close at T+365 US$2.36
- -49.4%Entry US$8.30 · Close at T+365 US$4.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,528 of 26,248 companies
40.6
score / 100
Value22
Quality59
FCF yld-6.6%
Earn yld-3.2%
EV/EBITDA·
ROE31%
Gross mgn49%
Net mgn-13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.55
Analyst consensus
2 analysts1.00/5
US$10.00Target US$11.00(+331%)US$12.00
Income statement
RevenueUS$52.7M
Gross profitUS$25.8M49% margin
EBITDA-US$3M-6% margin
Net income-US$6.6M23.5% margin
Valuation
PER (trailing)11.1x
P/Book2.9x
Beta-0.09
Balance sheet & cash
Market capUS$205.5M
Total debtUS$8.3M
Free Cash Flow-US$13.6M
Debt / Equity13%
Profitability & ownership
ROE31.2%
ROA15.4%
% insiders3.9%
% institutions23.7%
Last declaration on 23 December 2025
Declarations35 total
56,000 shares@ US$1.8135.4% of flowCommon StockSEC:0001781450-25-000005:0
Canonical exit: 19 Mar 2026 (T+90)
168 shares@ US$1.87100.0% of flowCommon StockSEC:0001385113-25-000005:0
7,500 sharesCommon StockSEC:0001415889-25-023706:0
7,500 sharesCommon StockSEC:0001415889-25-023708:0
7,500 sharesCommon StockSEC:0001415889-25-023707:0
7,500 sharesCommon StockSEC:0001415889-25-023705:0
7,500 sharesCommon StockSEC:0001415889-25-023704:0
7,500 sharesCommon StockSEC:0001415889-25-023703:0
7,500 sharesCommon StockSEC:0001415889-25-023702:0
25,000 sharesCommon StockSEC:0001415889-25-023701:0
195,000 sharesCommon StockSEC:0001415889-25-023700:0
129,000 shares@ US$1.59655.2% of flowCommon StockSEC:0001415889-25-021494:0
Canonical exit: 8 Sept 2025 (T+90)
90,909 sharesCommon StockSEC:0001415889-24-026168:0
99,010 sharesCommon StockSEC:0001415889-24-023907:0
263,960 sharesCommon StockSEC:0001415889-24-010099:0
16,129 shares@ US$1.418.1% of flowCommon StockSEC:0001415889-23-014454:1
Canonical exit: 17 Jan 2024 (T+90)
48,387 shares@ US$1.4026.2% of flowCommon StockSEC:0001415889-23-014454:0
Canonical exit: 17 Jan 2024 (T+90)
800,000 sharesCommon StockSEC:0001104659-23-093073:0
187,344 sharesCommon StockSEC:0001104659-23-093066:0
35,115 sharesCommon StockSEC:0001104659-23-093069:0
201,903 sharesCommon StockSEC:0001104659-23-093070:0
110,000 shares@ US$1.416544.8% of flowCommon StockSEC:0001104659-23-001495:0
Canonical exit: 3 Apr 2023 (T+90)
68,000 shares@ US$1.5038.4% of flowCommon StockSEC:0001104659-22-045488:0
Canonical exit: 10 Jul 2022 (T+90)
121,951 sharesCommon StockSEC:0001104659-22-028159:0
637,531 sharesCommon StockSEC:0001104659-22-028157:0
25 of 35 declarations
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on NYSE American (NYSE/NASDAQ context) and incorporated in the United States, while its operating base and scientific footprint are primarily in Israel. For French-speaking investors, PLX is best understood as a niche rare-disease biotech focused on the discovery, development, production, and commercialization of recombinant therapeutic proteins. Its core differentiator is ProCellEx®, a proprietary plant cell-based protein expression platform that underpins both its commercial assets and its development pipeline.
From a strategic standpoint, Protalix has built its business around high-unmet-need rare diseases rather than broad primary-care markets. That approach generally implies smaller patient populations, higher scientific complexity, and meaningful regulatory hurdles, but it can also support premium pricing, orphan-drug economics, and stronger product differentiation if clinical and commercial execution is successful. The company’s lead commercial product is Elfabrio® (pegunigalsidase alfa), approved for adult patients with Fabry disease. Elfabrio is central to the company’s near-term revenue base and is commercialized through a partnership model, including Chiesi across key markets. This gives Protalix access to broader commercial reach while limiting the need to build a fully integrated global sales infrastructure on its own.
Read moreShow less
Another important historical asset is taliglucerase alfa, Protalix’s first product manufactured using ProCellEx, for Gaucher disease. Protalix licensed worldwide development and commercialization rights to Pfizer, except in Brazil where Protalix retains full rights. That partnership remains strategically relevant because it validates the platform and provides an additional, albeit selective, revenue opportunity. Beyond marketed products, the pipeline includes PRX-115, a plant cell-expressed recombinant PEGylated uricase being developed for uncontrolled gout, and PRX-119, a long-acting DNase I candidate aimed at NETs-related diseases. In other words, the company is trying to extend a single manufacturing and biology platform across multiple specialty indications.
Competitively, Protalix does not operate as a large-cap pharma company; it competes with better-financed biotech and pharmaceutical peers, but seeks to offset that disadvantage through technological specialization, focused indication selection, and strategic partnerships. Its geographic presence is notable: the company is a U.S. public issuer, yet its operational narrative is closely tied to Israel. Recent milestones are important for investors: 2025 filings and press releases highlighted stronger revenue momentum, an IND submission for PRX-115 in October 2025, and inclusion in the Russell 3000 and Russell 2000 indexes in June 2025. Overall, PLX is a specialized rare-disease biotech with a credible platform story, a commercial product in Fabry disease, and a pipeline that offers upside but remains subject to the execution, clinical, regulatory, and partnership risks typical of the sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
